Bone Sarcoma Clinical Trial
Official title:
3D Gait Analysis to Determine Functional Limitations and Evaluate a Training Intervention in Young People With Tumor Endoprosthesis of the Lower Extremity
The proGait-study is a two-arm exercise intervention study for AYA-patients with lower extremity tumor endoprosthesis in the follow-up care. This clinical trial will investigate the effects of an 8-week personalized multi-modal exercise intervention of lower extremity muscles on gait quality in adolescents and young adults with cancer diagnosis beginning at least 12 months after endoprosthesis implantation.
The main objective of the proGait-study is to investigate the effects of an 8-week personalized, partially supervised exercise program for lower extremity muscles on gait kinematics of adolescents and young adults, who are in follow-up care after cancer treatment and at least 12 months after endoprosthesis implantation. This randomized controlled trial will include n=20-30 patients. Patients will be randomly assigned to the intervention or control group. Patients in the intervention group will perform two supervised exercise sessions in week one and two. In the following weeks, they will perform in a mix of supervised and unsupervised exercise sessions to introduce the patients into independent exercise. Both groups receive recommendations for individual lower extremity exercise. Secondary aims of this interventional study are to evaluate functional mobility, knee range of motion and patient-reported outcomes including QoL and fatigue. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05621668 -
A First-In-Human Phase 1 Trial of T-Cell Membrane-Anchored Tumor Targeted Il12 (Attil12)- T-Cell Therapy in Subjects With Advanced/Metastatic Soft Tissue and Bone Sarcoma
|
Phase 1 | |
| Not yet recruiting |
NCT05515068 -
Registry For Children, Adolescents And Adults With Osteosarcoma And Biologically Related Bone Sarcomas
|
||
| Withdrawn |
NCT04906876 -
A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas
|
Phase 2 | |
| Active, not recruiting |
NCT00592293 -
Proton Radiation for the Treatment of Pediatric Bone and Non-Rhabdomyosarcoma Soft Tissue Sarcomas
|
N/A | |
| Recruiting |
NCT05051059 -
Assessment of the Functional Outcome and Quality of Life in Sarcoma Patients
|
N/A | |
| Recruiting |
NCT06129903 -
Study Assessing the Effects of Early Psychiatric Referral on Mental Health and Quality of Life in People With Sarcoma
|
N/A | |
| Completed |
NCT06202599 -
Fruquintinib-based Treatment for Refractory Bone and Soft Tissue Sarcomas After Several Lines of TKIs' Resistance
|
||
| Recruiting |
NCT04634227 -
Gemcitabine Plus Ascorbate for Sarcoma in Adults (Pilot)
|
Early Phase 1 | |
| Recruiting |
NCT03277924 -
Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03462316 -
NY-ESO-1-specific T Cell Receptor (TCR) T Cell in Sarcoma
|
Phase 1 | |
| Recruiting |
NCT04055220 -
Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas
|
N/A | |
| Completed |
NCT02520128 -
A Study of IMRT in Primary Bone and Soft Tissue Sarcoma
|
N/A | |
| Completed |
NCT02301039 -
SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas
|
Phase 2 | |
| Withdrawn |
NCT05116800 -
Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma
|
Phase 2 | |
| Recruiting |
NCT04181970 -
Observational Study, for Quality Assessment, of Sarcoma in European and Latin American Multidisciplinary NETWORK
|
||
| Completed |
NCT00525057 -
Dalteparin in Preventing DVT in Participants With Cancer
|
N/A | |
| Recruiting |
NCT04698785 -
Efficacy of Regorafenib Combined With Best Supportive Care as Maintenance Treatment in High Grade Bone Sarcomas Patients
|
Phase 2 | |
| Completed |
NCT01588522 -
Compound 31543 (Calcitriol, USP) in Patients Receiving Taxane-based Chemotherapy Regimens for Advanced or Recurrent Disease
|
Phase 1 | |
| Terminated |
NCT03468075 -
Gemcitabine Plus Ascorbate for Sarcoma in Adults
|
Phase 2 | |
| Recruiting |
NCT04616248 -
In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors
|
Phase 1 |